上海复宏汉霖生物技术股份有限公司（02696）于2026年2月4日发布翌日披露报表，公告显示公司已将182,645,856股非上市股转换为等量H股。
上述变动占转换前已发行股份总数的33.61%。转换后，H股由原先的163,428,541股增至346,074,397股；同时，非上市股份从380,066,312股降至197,420,456股。
公司在公告中确认，本次股份变动已通过董事会审批，所有程序符合香港联合交易所有限公司证券上市规则及适用法律法规。
公告由公司董事Wenjie ZHANG签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.